Obesity Market
-
{
- All
- News
- Videos
-
With Rs 13,000-25,000 Per Dose, Weight-Loss Drugs Are Changing Indian Weddings For Brides
The lowest Mounjaro injection pen dose sells for Rs 13,125 per month, while the highest dose costs Rs 25,781. Novo is selling the lowest Wegovy dose for Rs 5,660 and the highest for Rs 16,400 a month
-
Screen Time And Junk Food: Key Factors In Childhood Obesity Every Parent Should Know
By addressing the influences of screen time and junk food, and by implementing healthy habits, parents can help combat childhood obesity and promote a healthier lifestyle for their children.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
The Lancet Reports A Boom In Fake Obesity Drugs: What You Need To Know
A new Lancet report pinpoints that a boom in counterfeit obesity drugs is taking place. Here is what you need to know about the dangers that these drugs pose and why following the properly established medical guidance is key to being safe.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
World Obesity Day 2026: India's Child Obesity Numbers Soar, Ranks 2nd Worldwide
India ranks second globally for children living with overweight and obesity, warns the World Obesity Atlas 2026. With 41 million affected and sharp rises projected by 2040, experts urge urgent policy action, including sugar taxes and marketing curbs.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
From Obesity To Rising Healthcare Costs, Why India Needs An Urgent War On Junk Food
The Economic Survey 2025-26 highlights ultra-processed foods as a public health concern linked to chronic diseases, obesity, and health inequalities, urging timely policy action.
-
Ban Advertising Of Ultra-Processed Foods From 6 Am-11 Pm: Economic Survey
Raising concerns on the growing consumption of ultra-processed foods containing high fat, salt and sugar amid India becoming one of the fastest growing markets for such items in the world, the Economic Survey has pitched for a ban on their ads.
-
Obesity Rising At Alarming Rate, Unhealthy Diets And Lifestyle Changes Responsible: Economic Survey 2025-26
Obesity is rising at an alarming rate and is today a major public health challenge in India, said Economic Survey for 2025-26 on Thursday.
-
Ozempic Too Costly? 7 Cheaper And Clinically Approved Alternatives Available In India
Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives which can also aid in weight loss?
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg Intelligence estimates will reach $100 billion in annual sales by 2030.
-
With Rs 13,000-25,000 Per Dose, Weight-Loss Drugs Are Changing Indian Weddings For Brides
The lowest Mounjaro injection pen dose sells for Rs 13,125 per month, while the highest dose costs Rs 25,781. Novo is selling the lowest Wegovy dose for Rs 5,660 and the highest for Rs 16,400 a month
-
Screen Time And Junk Food: Key Factors In Childhood Obesity Every Parent Should Know
By addressing the influences of screen time and junk food, and by implementing healthy habits, parents can help combat childhood obesity and promote a healthier lifestyle for their children.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
The Lancet Reports A Boom In Fake Obesity Drugs: What You Need To Know
A new Lancet report pinpoints that a boom in counterfeit obesity drugs is taking place. Here is what you need to know about the dangers that these drugs pose and why following the properly established medical guidance is key to being safe.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
World Obesity Day 2026: India's Child Obesity Numbers Soar, Ranks 2nd Worldwide
India ranks second globally for children living with overweight and obesity, warns the World Obesity Atlas 2026. With 41 million affected and sharp rises projected by 2040, experts urge urgent policy action, including sugar taxes and marketing curbs.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
From Obesity To Rising Healthcare Costs, Why India Needs An Urgent War On Junk Food
The Economic Survey 2025-26 highlights ultra-processed foods as a public health concern linked to chronic diseases, obesity, and health inequalities, urging timely policy action.
-
Ban Advertising Of Ultra-Processed Foods From 6 Am-11 Pm: Economic Survey
Raising concerns on the growing consumption of ultra-processed foods containing high fat, salt and sugar amid India becoming one of the fastest growing markets for such items in the world, the Economic Survey has pitched for a ban on their ads.
-
Obesity Rising At Alarming Rate, Unhealthy Diets And Lifestyle Changes Responsible: Economic Survey 2025-26
Obesity is rising at an alarming rate and is today a major public health challenge in India, said Economic Survey for 2025-26 on Thursday.
-
Ozempic Too Costly? 7 Cheaper And Clinically Approved Alternatives Available In India
Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives which can also aid in weight loss?
-
Ozempic, Type 2 Diabetes, Weight Loss Drug Launched In India. Check Price
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
-
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
Oral versions of popular weight-loss shots are some of the next big things in the obesity market, which Bloomberg Intelligence estimates will reach $100 billion in annual sales by 2030.
